Appointment of Philippe MAUBERNA, CFO of Nanobiotix (since May 2013) to the Executive Board and creation of a Communications and Public Affairs Department headed by Sarah Gaubert
Paris, France – 23 September 2013 – NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today the strengthening of its management team to support the company’s growth within its business strategy.
1. Appointment of Philippe MAUBERNA, CFO of Nanobiotix since the end of May 2013 to the Executive Board by the Supervisory Board effective from August 28, 2013
As expert in management and development of financial and operational projects for the pharmaceutical industry, Philippe MAUBERNA (ISG-INSEAD), has been involved in several international projects (UK, Saudi Arabia, South Africa and Indonesia). Dedicated to the Life Sciences industry for more than 10 years, he has held senior Financial and Operations positions at Astellas Pharma Europe participating in the reinforcement of EMEA commercial effectiveness in Africa and in Europe, most notably this was supporting market authorization for several healthcare products.
He has also been heavily involved in financial projects for start-up launches and innovative SME development. As a consultant, he has provided strategic change management support for European pharmaceutical companies during their development phases.
2. Creation of a Communication and Public Affairs Department headed up by Sarah Gaubert
Formerly advisor to the French Presidency and to several Ministries (Health, Solidarity, Education and Research), Sarah GAUBERT, consultant in strategic communications, heads Nanobiotix’ newly created Communication and Public Affairs Department.
“In order to meet our corporate governance requirements, there was a strong need to strengthen and structure the management team. Based on our business needs, Philippe Mauberna has the right mix of experience and competencies which will be key in supporting our growth. As a public company, we have the increasing responsibility to have a transparent and coordinated communication on our ambitious plans. This will be the challenge for Sarah Gaubert, expert in public and parliamentary affairs, who shares with the Nanobiotix team the notion of general interest and transmission” said Laurent Levy, CEO of Nanobiotix.
Notes to Editors
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration. Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma. The Company, based in Paris, France. has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.
Laurent Levy, CEO and co-founder of Nanobiotix, is the Vice-President of the European Technology Platform of Nanomedicine (ETPN).
For more information, please visit www.nanobiotix.com
Issued for and on behalf of Nanobiotix.
To contact the Nanobiotix team at College Hill, email email@example.com
Melanie Toyne-SewellManaging Partner